• Open Access

Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models

Authors

  • Ivo J. Huijbers,

    1. Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    2. Centre of Biomedical Genetics, Amsterdam, The Netherlands
    Search for more papers by this author
  • Paul Krimpenfort,

    1. Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    2. Centre of Biomedical Genetics, Amsterdam, The Netherlands
    Search for more papers by this author
  • Anton Berns,

    Corresponding author
    1. Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    2. Centre of Biomedical Genetics, Amsterdam, The Netherlands
    3. Academic Medical Center, Amsterdam, The Netherlands
    • Division of Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Search for more papers by this author
  • Jos Jonkers

    Corresponding author
    1. Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    • Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Search for more papers by this author

Abstract

Recent technological advances have opened the door for the fast and cost-effective generation of genetically engineered mouse models (GEMMs) to study cancer. We describe here a conceptually novel approach for the generation of chimeric GEMMs based on the controlled introduction of various genetic elements in embryonic stem cells (ESCs) that are derived from existing mouse strains with a predisposition for cancer. The isolation of GEMM-derived ESC lines is greatly facilitated by the availability of the newly defined culture media containing inhibitors that effectively preserve ESC pluripotency. The feasibility of the GEMM-ESC approach is discussed in light of current literature and placed into the context of existing models. This approach will allow for fast and flexible validation of candidate cancer genes and drug targets and will result in a repository of GEMM-ESC lines and corresponding vector collections that enable easy distribution and use of preclinical models to the wider scientific community.

Ancillary